29
Table 10. Checklist for Individualized Benefit-Risk Discussion
(cont'd)
Checklist Item Recommendation
✓
Cost and
convenience
considerations
• Discuss potential out-of-pocket cost of therapy to the
patient (eg, insurance plan coverage, tier level, copayment).
• Discuss administration of medicine by daily oral therapy,
time of administration, potential drug interactions,
subcutaneous injection every 2 weeks versus every 6 months.
✓
Shared
decision-making
• Encourage the patient to verbalize what was heard
(eg, patient's personal estimated ASCVD risk, available
options, and risks/benefits).
• Invite the patient to ask questions, express values and
preferences, and state ability to adhere to lifestyle changes
and medications.
• Refer patients to trustworthy materials to aid in their
understanding of issues regarding risk decisions.
• Collaborate with the patient to determine therapy and
follow-up plan.
* e PREVENT-ASCVD Online Calculator is available at:
https://professional.heart.org/en/guidelines-and-statements/prevent-calculator.
†
CardioSmart health information is available at: https://www.cardiosmart.org/topics/
healthy-living.
‡
AHA Life's Essential 8 information is available at:
https://www.heart.org/en/healthy-living/healthy-lifestyle/lifes-essential-8.
§
NLA Patient Tear Sheets information is available at:
https://www.lipid.org/practicetools/tools/tearsheets.
||
PCNA Heart Healthy Toolbox information is available at:
https://pcna.net/resource/heart-healthy-toolbox/.
AHA indicates American Heart Association; ASCVD, atherosclerotic cardiovascular disease;
CAC, coronary artery calcium; CT, computed tomography; ECG, electrocardiogram;
LDL-C, low-density lipoprotein-cholesterol; LLT, lipid-lowering therapy; PCNA, Preventive
Cardiolog y Nurses Association; and NLA, National Lipid Association.
Adapted with permission from Martin et al. Copyright © 2015 American College of
Cardiolog y Foundation.
